Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

ImmuCell Corporation (ICCC) vs Neuraxis, Inc. (NRXS)

ImmuCell Corporation and Neuraxis, Inc. are both Biotechnology companies. ImmuCell Corporation and Neuraxis, Inc. are of similar size ($97.3M and $90.6M). Neuraxis, Inc. has negative trailing earnings, so its P/E is not meaningful; ImmuCell Corporation trades at 117×. Neuraxis, Inc. grew revenue faster over the last twelve months: 65.2% against 8.49%. ImmuCell Corporation has the higher net margin (2.57% vs −159.0%) and the higher return on invested capital (7.84% vs 0.00%). Across the 18 metrics below, ImmuCell Corporation leads on 13 and Neuraxis, Inc. on 5.

Valuation

Metric ICCC NRXS Biotechnology median
P/E 117.38 n/m 7.88
P/S 2.93 17.24 11.47
P/B 2.87 13.61 2.52
Price to free cash flow 21.27 n/m 21.16
EV/EBITDA 14.22 n/m 0.74
EV/Sales 2.92 15.68 10.73
Earnings yield 0.85% (10.32%) (28.84%)
Free cash flow yield 4.70% (6.31%) (23.03%)

Profitability

Metric ICCC NRXS Biotechnology median
Gross margin 40.32% 85.56% 65.16%
Operating margin 12.60% (144.51%) 0.00%
Net margin 2.57% (159.01%) 0.00%
Free cash flow margin 13.79% (106.10%) 0.00%
Return on equity 2.57% (153.96%) (57.72%)
Return on assets 1.69% (98.96%) (49.22%)
Return on invested capital 7.84% 0.00% 0.00%

Growth

Metric ICCC NRXS Biotechnology median
Revenue growth (TTM) 8.49% 65.22% 5.64%
EPS growth (last fiscal year) 53.85% 22.13% —
Revenue growth, 5-year CAGR 12.50% 13.08% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ICCC NRXS Biotechnology median
Debt to equity 0.26 0.00 0.00
Current ratio 4.75 3.04 4.73
Net debt to EBITDA 1.19 0.64 0.96

Dividend

Metric ICCC NRXS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric ICCC NRXS Biotechnology median
Market cap 90.55m 97.32m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack